David W Griggs

US Patent:

7452537, Nov 18, 2008

Filed:

Apr 25, 2006

Appl. No.:

11/410610

Inventors:

Christopher Todd Bauer - St. Louis MO, US
Maureen Jeri Bourner - Defiance MO, US
Melanie Boyle - Granta Park, GB
Gerald Fries Casperson - Ballwin MO, US
David William Griggs - Ballwin MO, US
Richard David Head - O'Fallon MO, US
William Dean Joy - St. Louis MO, US
Richard Allen Mazzarella - Webster Groves MO, US
Ralph Raymond Minter - Cambridge, GB
Mark Allen Moffat - St. Louis MO, US
Barrett Richard Thiele - St. Louis MO, US
Todd Lee Vanarsdale - Carlsbad CA, US

Assignee:

Agouron Pharmaceuticals, Inc. - San Diego CA

International Classification:

A61K 39/00
C07K 16/00

US Classification:

4241331, 53038822

Abstract:

The present invention relates to antibodies including human antibodies and antigen-binding portions thereof that bind to P-cadherin, and that function to inhibit P-cadherin. The invention also relates to heavy and light chain immunoglobulins derived from human P-cadherin antibodies and nucleic acid molecules encoding such immunoglobulins. The present invention also relates to methods of making human P-cadherin antibodies, compositions comprising these antibodies and methods of using the antibodies and compositions. The invention also relates to transgenic animals or plants comprising nucleic acid molecules of the present invention.

US Patent:

7928214, Apr 19, 2011

Filed:

Oct 10, 2008

Appl. No.:

12/249843

Inventors:

Christopher Todd Bauer - St. Louis MO, US
Maureen Jeri Bourner - Defiance MO, US
Melanie Boyle - Granta Park, GB
Gerald Fries Casperson - Ballwin MO, US
David William Griggs - Ballwin MO, US
Richard David Head - O'Fallon MO, US
William Dean Joy - St. Louis MO, US
Richard Allen Mazzarella - Webster Groves MO, US
Ralph Raymond Minter - Granta Park, GB
Mark Allen Moffat - St. Louis MO, US
Barrett Richard Thiele - St. Louis MO, US
Todd Lee Vanarsdale - Carlsbad CA, US

Assignee:

Agouron Pharmaceuticals, Inc. - San Diego CA

International Classification:

C07H 21/04

US Classification:

536 2353

Abstract:

The present invention relates to antibodies including human antibodies and antigen-binding portions thereof that bind to P-cadherin, and that function to inhibit P-cadherin. The invention also relates to heavy and light chain immunoglobulins derived from human P-cadherin antibodies and nucleic acid molecules encoding such immunoglobulins. The present invention also relates to methods of making human P-cadherin antibodies, compositions comprising these antibodies and methods of using the antibodies and compositions. The invention also relates to transgenic animals or plants comprising nucleic acid molecules of the present invention.

US Patent:

20030232367, Dec 18, 2003

Filed:

Apr 11, 2003

Appl. No.:

10/412548

Inventors:

Edward Weinstein - Chesterfield MO, US
Richard Head - Florissant MO, US
Richard Mazzarella - Webster Groves MO, US
David Griggs - Ballwin MO, US

International Classification:

C12Q001/68
G01N033/574
C07H021/04
A61K039/395
C12N009/64
C12P021/02
C12N005/06
C07K016/40

US Classification:

435/006000, 435/007230, 435/069100, 435/226000, 435/320100, 435/325000, 530/388260, 424/146100, 536/023200

Abstract:

The invention relates generally to the identification of nucleic acids and their encoded polypeptides, particularly VCC1, whose expression is modulated in angiogenesis. These nucleic acids and proteins have not previously been identified as having a biological role in angiogenesis. The invention further relates to compounds that modulate VCC1 expression and/or activity. Methods of using these compounds for modulation of VCC-1 expression and for treatment of diseases associated with expression of VCC-1 are provided. Also included are methods of diagnosis of VCC1 associated angiogenic disorders.

US Patent:

20040167067, Aug 26, 2004

Filed:

Jul 1, 2003

Appl. No.:

10/611527

Inventors:

David Griggs - Ballwin MO, US
Richard Head - Florissant MO, US
Richard Mazzarella - Webster Groves MO, US
Edward Weinstein - Lansdale PA, US

International Classification:

A61K038/17
C07K014/705
C07H021/04

US Classification:

514/012000, 530/350000, 435/069100, 435/320100, 435/325000, 536/023500

Abstract:

The invention relates a nucleic acid and its encoded polypeptide ESM-1, whose expression is modulated in angiogenesis and oncogenesis. The invention also relates to antibodies having specificity for said polypeptide. The present invention also relates to antisense molecules. The invention further relates to methods useful for treating or modulating angiogenesis in mammals in need of such biological effect.

US Patent:

20110182884, Jul 28, 2011

Filed:

Apr 4, 2011

Appl. No.:

13/079726

Inventors:

Christopher Todd Bauer - St. Louis MO, US
Maureen Jeri Bourner - Defiance MO, US
Melanie Boyle - Granta Park, GB
Gerald Fries Casperson - Ballwin MO, US
David William Griggs - Ballwin MO, US
Richard David Head - O'Fallon MO, US
William Dean Joy - St. Louis MO, US
Richard Allen Mazzarella - Webster Groves MO, US
Ralph Raymond Minter - Granta Park, GB
Mark Allen Moffat - St. Louis MO, US
Barrett Richard Thiele - St. Louis MO, US
Todd Lee Vanarsdale - Carlsbad CA, US

International Classification:

A61K 39/395
C07K 16/18
A61P 35/00
A61P 35/02

US Classification:

4241301, 5303891

Abstract:

The present invention relates to antibodies including human antibodies and antigen-binding portions thereof that bind to P-cadherin, and that function to inhibit P-cadherin. The invention also relates to heavy and light chain immunoglobulins derived from human P-cadherin antibodies and nucleic acid molecules encoding such immunoglobulins. The present invention also relates to methods of making human P-cadherin antibodies, compositions comprising these antibodies and methods of using the antibodies and compositions. The invention also relates to transgenic animals or plants comprising nucleic acid molecules of the present invention.

US Patent:

20140038910, Feb 6, 2014

Filed:

Jul 17, 2013

Appl. No.:

13/944599

Inventors:

David GRIGGS - Ballwin MO, US

Assignee:

Saint Louis University - St. Louis MO

International Classification:

C07K 5/06

US Classification:

514 2191, 544298, 562439, 514563, 546306, 514353, 5483321, 514401, 5483331, 544296, 558414, 560 42, 549426

Abstract:

Disclosed herein are novel pharmaceutical agents which are useful as integrin receptor antagonists that mediate the pathologic processes of angiogenesis and fibrosis and as such are useful in pharmaceutical compositions and in methods for treating conditions mediated by these integrins by inhibiting or antagonizing these integrins. The novel pharmaceutical agents include those of the formula:wherein the variables are defined herein. Also provided are pharmaceutical compositions, kits and articles of manufacture comprising such pharmaceutical agents. Methods and intermediates useful for making the pharmaceutical agents and methods of using the pharmaceutical agents are also provided.

US Patent:

20140051715, Feb 20, 2014

Filed:

Jul 17, 2013

Appl. No.:

13/944319

Inventors:

David GRIGGS - Ballwin MO, US

Assignee:

Saint Louis University - St. Louis MO

International Classification:

C07D 239/14

US Classification:

514272, 544332

Abstract:

Disclosed herein are novel pharmaceutical agents which are useful as integrin receptor antagonists that mediate the pathologic processes of angiogenesis and fibrosis and as such are useful in pharmaceutical compositions and in methods for treating conditions mediated by these integrins by inhibiting or antagonizing these integrins. The novel pharmaceutical agents include those of the formula:wherein X is bromo or iodo, or pharmaceutically acceptable salts thereof. Also provided are pharmaceutical compositions, kits and articles of manufacture comprising such pharmaceutical agents. Methods and intermediates useful for making the pharmaceutical agents and methods of using the pharmaceutical agents are also provided.

US Patent:

20200199079, Jun 25, 2020

Filed:

Mar 2, 2020

Appl. No.:

16/806963

Inventors:

- St. Louis MO, US
David W. Griggs - Ballwin MO, US

International Classification:

C07D 239/14
C07D 401/12
C07D 239/16
C07D 239/02
C07D 233/28

Abstract:

The present disclosure provides pharmaceutical agents of the formula:wherein the variables are defined herein. Also provided are pharmaceutical compositions, kits and articles of manufacture comprising such pharmaceutical agents. Methods of using the pharmaceutical agents for the treatment of a variety of diseases and disorders are also provided.